Statin myopathy: over-rated and under-treated?. (July 2016)

• Record Type: Journal Article
• Authors: Maghsoodi, Negar; Wierzbicki, Anthony S.
• Is Part Of: Current opinion in cardiology. Volume 31:Number 4(2016:Jul.)
• Page Start: 417
• Page End: 425
• Publication Date: 2016-07
• Subjects: muscle -- myalgia -- myopathy -- rhabdomyolysis -- statin -- treatment; Cardiology -- Periodicals; Cardiology -- Periodicals; Heart Diseases -- Periodicals; Cardiology; Periodicals; 616.12
• DOI: 10.1097/HCO.0000000000000282
• Languages: English
• ISSNs: 0268-4705

Abstract

Abstract : Purpose of review: Statins are recommended as first-line therapy for cardiovascular disease. Unfortunately, a proportion of patients cannot tolerate these drugs because of muscle-related side-effects. This review summarizes the definition of statin-related muscle disorders, aetiological factors, and recommended management strategies. Recent findings: A number of consensus groups have defined and classified statin-related muscle disorders, whereas others have suggested diagnostic and management strategies. Mechanisms behind statin-related muscle toxicity have been identified. Therapeutic and clinical investigation pathways have been reviewed and algorithms defined. New drugs have become available to reduce low-density lipoprotein cholesterol levels that are not associated with causing muscle side-effects. Summary: Statin-related muscle side-effects are common. Secondary causes of muscle disease unmasked by statin therapy should be identified. Most patients can be managed by adjustment of standard treatment protocols.